FLOMAX Drug Patent Profile
✉ Email this page to a colleague
When do Flomax patents expire, and when can generic versions of Flomax launch?
Flomax is a drug marketed by Sanofi and is included in one NDA.
The generic ingredient in FLOMAX is tamsulosin hydrochloride. There are thirty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the tamsulosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flomax
A generic version of FLOMAX was approved as tamsulosin hydrochloride by IMPAX LABS on March 2nd, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FLOMAX?
- What are the global sales for FLOMAX?
- What is Average Wholesale Price for FLOMAX?
Summary for FLOMAX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 46 |
| Patent Applications: | 1,795 |
| Drug Prices: | Drug price information for FLOMAX |
| Drug Sales Revenues: | Drug sales revenues for FLOMAX |
| What excipients (inactive ingredients) are in FLOMAX? | FLOMAX excipients list |
| DailyMed Link: | FLOMAX at DailyMed |
Recent Clinical Trials for FLOMAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hackensack Meridian Health | N/A |
| St. Joseph's Healthcare Hamilton | Phase 4 |
| NeoTract, Inc. | Phase 4 |
Pharmacology for FLOMAX
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Paragraph IV (Patent) Challenges for FLOMAX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| FLOMAX | Capsules | tamsulosin hydrochloride | 0.4 mg | 020579 | 1 | 2004-12-20 |
US Patents and Regulatory Information for FLOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi | FLOMAX | tamsulosin hydrochloride | CAPSULE;ORAL | 020579-001 | Apr 15, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FLOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi | FLOMAX | tamsulosin hydrochloride | CAPSULE;ORAL | 020579-001 | Apr 15, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi | FLOMAX | tamsulosin hydrochloride | CAPSULE;ORAL | 020579-001 | Apr 15, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi | FLOMAX | tamsulosin hydrochloride | CAPSULE;ORAL | 020579-001 | Apr 15, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi | FLOMAX | tamsulosin hydrochloride | CAPSULE;ORAL | 020579-001 | Apr 15, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FLOMAX
See the table below for patents covering FLOMAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | H0772129 | ⤷ Sign Up | |
| European Patent Office | 0194838 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION | ⤷ Sign Up |
| Spain | 8201966 | ⤷ Sign Up | |
| Greece | 73827 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLOMAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0034432 | SPC/GB96/017: EXPIRE | United Kingdom | ⤷ Sign Up | SPC/GB96/017: EXPIRES: 20060201 |
| 0034432 | 96C0048 | Belgium | ⤷ Sign Up | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
